{"id":32795,"date":"2025-04-30T22:10:58","date_gmt":"2025-04-30T14:10:58","guid":{"rendered":"https:\/\/flcube.com\/?p=32795"},"modified":"2025-04-30T22:10:59","modified_gmt":"2025-04-30T14:10:59","slug":"dizal-pharmaceutical-reports-strong-revenue-growth-in-2024-and-q1-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32795","title":{"rendered":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025"},"content":{"rendered":"\n<p>China-based Dizal Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).<\/p>\n\n\n\n<p><strong>Key Developments and Sales Performance<\/strong><br>In November 2024, the company&#8217;s EGFR inhibitor sunvozertinib and JAK1 inhibitor Gaoruizhe (golidocitinib) were included in the National Reimbursement Drug List (NRDL), driving rapid sales growth. Sunvozertinib is currently awaiting regulatory decisions in the US with priority review status.<\/p>\n\n\n\n<p><strong>Financial Metrics and Cost Management<\/strong><br>While achieving significant sales growth, Dizal Pharmaceutical managed to reduce its sales expense ratio to 77% in Q1 2025, compared to 124% for the entire year of 2024. Research and development expenses have remained stable and slightly decreased over the past two years, despite the launch of two in-house developed innovative drugs.<\/p>\n\n\n\n<p><strong>Net Loss and Future Outlook<\/strong><br>During the reporting period in 2024, the net loss attributable to the shareholders of the parent company was approximately RMB 850 million (USD 117 million), a 24% decrease YOY. In the first quarter of 2025, the net loss attributable to shareholders of the parent company was approximately RMB 190 million (USD 26 million), a 14% drop.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495722_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202504291664495722_1.\"><\/object><a id=\"wp-block-file--media-a3538c69-b419-4eec-bf98-220275702129\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495722_1.pdf\">H2_AN202504291664495722_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495722_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a3538c69-b419-4eec-bf98-220275702129\">Download<\/a><\/div>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495694_1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of H2_AN202504291664495694_1.\"><\/object><a id=\"wp-block-file--media-c7c6b722-d867-466b-85ce-6fc6fce7cd05\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495694_1.pdf\">H2_AN202504291664495694_1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/H2_AN202504291664495694_1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c7c6b722-d867-466b-85ce-6fc6fce7cd05\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[191,27,981],"class_list":["post-32795","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-dizal-pharmaceutical","tag-finanical-reports","tag-sha-688192"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32795\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025\" \/>\n<meta property=\"og:description\" content=\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32795\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-30T14:10:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-30T14:10:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025\",\"datePublished\":\"2025-04-30T14:10:58+00:00\",\"dateModified\":\"2025-04-30T14:10:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795\"},\"wordCount\":213,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3017.webp\",\"keywords\":[\"Dizal Pharmaceutical\",\"Finanical Reports\",\"SHA: 688192\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32795#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32795\",\"name\":\"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3017.webp\",\"datePublished\":\"2025-04-30T14:10:58+00:00\",\"dateModified\":\"2025-04-30T14:10:59+00:00\",\"description\":\"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32795\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3017.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/3017.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32795#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32795","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025","og_description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).","og_url":"https:\/\/flcube.com\/?p=32795","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-30T14:10:58+00:00","article_modified_time":"2025-04-30T14:10:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32795#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32795"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025","datePublished":"2025-04-30T14:10:58+00:00","dateModified":"2025-04-30T14:10:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32795"},"wordCount":213,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32795#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","keywords":["Dizal Pharmaceutical","Finanical Reports","SHA: 688192"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32795#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32795","url":"https:\/\/flcube.com\/?p=32795","name":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32795#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32795#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","datePublished":"2025-04-30T14:10:58+00:00","dateModified":"2025-04-30T14:10:59+00:00","description":"China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1 2025 financial performance. In 2024, the company generated RMB 360 million (USD 49.5 million) in revenues, a 294% year-on-year (YOY) increase. In the first quarter of 2025, operating revenue soared by 96% YOY to RMB 160 million (USD 22 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32795#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32795"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32795#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","width":1080,"height":608,"caption":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32795#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/3017.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32795"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32795\/revisions"}],"predecessor-version":[{"id":32799,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32795\/revisions\/32799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32798"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}